CCM
VRCA icon

Coldstream Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Coldstream Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-71
Closed -$315 – 3306
2025
Q1 		$315 Buy
+71
New +$459 ﹤0.01% 3438

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Coldstream Capital Management's VRCA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 71 shares — an estimated $315 sold.

Coldstream Capital Management first reported a position in VRCA in Q1 2025 and held it in 1 quarter. The position peaked at $315 in Q1 2025. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 71 Verrica Pharmaceuticals shares in Q2 2025, an estimated $315.
  • Coldstream Capital Management first reported a position in Verrica Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Verrica Pharmaceuticals position peaked at $315 in Q1 2025.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.